Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590313 | 1.00 | GRM2 (0.39) | GRM2DRD2DRD4KCNH2 | |
| SCHEMBL590312 | 1.00 | GRM2 (0.39) | GRM2DRD2DRD4KCNH2 | |
| SCHEMBL590956 | 0.88 | KCNH2 (0.38) | DRD2DRD4KCNH2 | |
| SCHEMBL591277 | 0.88 | KCNH2 (0.38) | DRD2DRD4KCNH2 | |
| SCHEMBL591513 | 0.88 | KCNH2 (0.38) | DRD2DRD4KCNH2 | |
| SCHEMBL592199 | 0.88 | KCNH2 (0.38) | DRD2DRD4KCNH2 | |
| SCHEMBL590345 | 0.88 | KCNH2 (0.38) | DRD2DRD4KCNH2 | |
| SCHEMBL591698 | 0.87 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL590289 | 0.87 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL590049 | 0.87 | KCNH2 (0.40) | GRM2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114867-B2 | Oxazolidinone antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | OXA1L, XDH, CCNY | GRM2 4516/4885DRD2 152/4885DRD4 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.